Concepedia

Bromodomain 4 inhibition leads to <i>MYCN</i> downregulation in Wilms tumor

Andrew D. Woods, Noah Berlow, Michael V. Ortiz, Filemon S. Dela Cruz, Armaan Siddiquee, Diego F. Coutinho, Reshma Purohit, Katherine E. Tranbarger Freier, Joel Michalek, Melvin Lathara,

Pediatric Blood & Cancer · 2021 · 14 citations · 41 references

DOIFull text

Open access

Abstract

We suggest that AZD5153, a novel dual-BRD4 inhibitor, can reduce MYCN levels in both anaplastic and nonanaplastic Wilms tumor cell lines, reduces tumor volume in Wilms tumor PDXs, and should be further explored for its therapeutic potential.

References

41

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text

, , +7

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

Johannes Zuber, Junwei Shi, Eric Wang et al. · Nature · 2011 · 1.9K citations

, , +7

Histopathology and prognosis of Wilms tumorResults from the first national wilms' tumor study

J. Bruce Beckwith, New Palmer · Cancer · 1978 · 1.3K citations

, , +12

The genetic landscape of high-risk neuroblastoma

Trevor J. Pugh, Olena Morozova, Edward F. Attiyeh et al. · Nature Genetics · 2013 · 1.2K citations · Full text

Recruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4

Zhiyuan Yang, Jasper H. N. Yik, Ruichuan Chen et al. · Molecular Cell · 2005 · 1.1K citations · Full text

, , +9